Option Care Health (NASDAQ:OPCH) Cut to Hold at Wall Street Zen

Option Care Health (NASDAQ:OPCH) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

Several other research analysts have also recently issued reports on the company. TD Cowen dropped their price objective on Option Care Health from $30.00 to $27.00 and set a “hold” rating on the stock in a research note on Monday, November 3rd. Morgan Stanley assumed coverage on Option Care Health in a research note on Friday, October 17th. They set an “overweight” rating and a $35.00 price target on the stock. Citizens Jmp lowered their price objective on shares of Option Care Health from $38.00 to $36.00 and set a “market outperform” rating for the company in a research note on Friday, October 31st. Deutsche Bank Aktiengesellschaft increased their target price on shares of Option Care Health from $31.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Barrington Research reissued an “outperform” rating and set a $38.00 target price on shares of Option Care Health in a research report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Option Care Health presently has an average rating of “Moderate Buy” and an average target price of $36.27.

Option Care Health Trading Up 1.0%

OPCH stock opened at $33.24 on Friday. Option Care Health has a 12 month low of $22.29 and a 12 month high of $35.53. The firm’s 50-day moving average is $28.74 and its 200 day moving average is $29.34. The company has a market capitalization of $5.28 billion, a PE ratio of 26.38, a P/E/G ratio of 2.24 and a beta of 0.80. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.56 and a quick ratio of 1.05.

Insider Buying and Selling

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. acquired 38,000 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were acquired at an average cost of $25.98 per share, with a total value of $987,240.00. Following the acquisition, the director directly owned 413,390 shares of the company’s stock, valued at approximately $10,739,872.20. The trade was a 10.12% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.64% of the company’s stock.

Institutional Investors Weigh In On Option Care Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. USA Financial Formulas purchased a new position in shares of Option Care Health during the 2nd quarter valued at approximately $26,000. Cornerstone Planning Group LLC raised its position in Option Care Health by 7,621.4% during the third quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock worth $30,000 after acquiring an additional 1,067 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in Option Care Health by 1,492.9% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 892 shares of the company’s stock valued at $31,000 after purchasing an additional 836 shares in the last quarter. Advisory Services Network LLC acquired a new stake in shares of Option Care Health in the third quarter valued at about $35,000. Finally, McIlrath & Eck LLC purchased a new stake in shares of Option Care Health during the second quarter worth about $37,000. 98.05% of the stock is owned by institutional investors and hedge funds.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.